Psyence Biomedical Enters Conditional Binding Term Sheet For Proposed Acquisition Of Privately-held Clairvoyant Therapeutics
Portfolio Pulse from Benzinga Newsdesk
Psyence Biomedical has entered a conditional binding term sheet to acquire Clairvoyant Therapeutics. The acquisition involves issuing $500,000 in common shares and potential additional payments based on milestone achievements. Psyence will also provide up to $1.80 million to settle Clairvoyant's liabilities.
September 06, 2024 | 11:32 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Psyence Biomedical is acquiring Clairvoyant Therapeutics, issuing $500,000 in shares and potentially more based on milestones. This could impact Psyence's financials and stock price.
The acquisition of Clairvoyant Therapeutics by Psyence Biomedical involves issuing shares and advancing funds, which could affect Psyence's financial position and stock price. The potential for milestone-based payments adds uncertainty but also opportunity for growth.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100